Literature DB >> 30791782

Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.

Luis Calzadilla Bertot1, Leon A Adams1,2.   

Abstract

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and is associated with hepatocellular carcinoma (HCC), the most frequent malignant liver tumor. The increasing prevalence of obesity and diabetes is influencing the epidemiology of HCC with the most dramatic increases in NAFLD-related HCC seen in Western countries. Although cirrhosis is the major risk factor for HCC in NAFLD, there is increasing recognition that NAFLD-HCC occurs in the absence of cirrhosis. Areas covered: The epidemiology of NAFLD related HCC and its impact on changing the incidence of HCC globally. We overview risk factors for NAFLD-HCC in the presence and absence of cirrhosis and examine trends in liver transplantation (LT) related to NAFLD-HCC. Expert commentary: The incidence of NAFLD-related cirrhosis will continue to rise globally in parallel with risk factors of obesity and diabetes. Consequently, NAFLD-related HCC will become an increasingly important cause of liver-related morbidity and mortality and a common indication for LT worldwide. Further identification of risk factors for NAFLD-HCC and effective treatments for NAFLD are required to reduce this future burden of disease.

Entities:  

Keywords:  Non-alcoholic fatty liver disease; epidemiology; hepatocellular carcinoma; liver cirrhosis; liver transplantation; non-alcoholic steatohepatitis

Mesh:

Year:  2018        PMID: 30791782     DOI: 10.1080/17474124.2019.1549989

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  21 in total

1.  Sorafenib and metformin: to be, or not to be, that is the question.

Authors:  Giulia Orsi; Andrea Casadei-Gardini
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

Review 2.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

3.  Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience.

Authors:  Giulia Rovesti; Giulia Orsi; Andrikou Kalliopi; Caterina Vivaldi; Giorgia Marisi; Luca Faloppi; Francesco Giuseppe Foschi; Nicola Silvestris; Irene Pecora; Giuseppe Aprile; Eleonora Molinaro; Laura Riggi; Paola Ulivi; Matteo Canale; Alessandro Cucchetti; Emiliano Tamburini; Giorgio Ercolani; Lorenzo Fornaro; Pietro Andreone; Patrizia Zavattari; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Journal:  Gastrointest Tumors       Date:  2019-09-12

Review 4.  From the origin of NASH to the future of metabolic fatty liver disease.

Authors:  Andreas Geier; Dina Tiniakos; Helmut Denk; Michael Trauner
Journal:  Gut       Date:  2021-02-25       Impact factor: 23.059

5.  International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma.

Authors:  Amit G Singal; Yujin Hoshida; David J Pinato; Jorge Marrero; Jean-Charles Nault; Valerie Paradis; Nabihah Tayob; Morris Sherman; Young Suk Lim; Ziding Feng; Anna S Lok; Jo Ann Rinaudo; Sudhir Srivastava; Josep M Llovet; Augusto Villanueva
Journal:  Gastroenterology       Date:  2021-03-09       Impact factor: 33.883

Review 6.  Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.

Authors:  Yu Xu; Wei Guo; Cheng Zhang; Feiyu Chen; Hor Yue Tan; Sha Li; Ning Wang; Yibin Feng
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

7.  Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats.

Authors:  Agnieszka Karbownik; Danuta Szkutnik-Fiedler; Andrzej Czyrski; Natalia Kostewicz; Paulina Kaczmarska; Małgorzata Bekier; Joanna Stanisławiak-Rudowicz; Marta Karaźniewicz-Łada; Anna Wolc; Franciszek Główka; Edmund Grześkowiak; Edyta Szałek
Journal:  Pharmaceutics       Date:  2020-06-28       Impact factor: 6.321

Review 8.  AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review.

Authors:  Heather Patton; Julie Heimbach; Arthur McCullough
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 11.382

9.  The genetic association between type 2 diabetic and hepatocellular carcinomas.

Authors:  Zhan Shi; Zunqiang Xiao; Linjun Hu; Yuling Gao; Junjun Zhao; Yang Liu; Guoliang Shen; Qiuran Xu; Dongsheng Huang
Journal:  Ann Transl Med       Date:  2020-03

10.  Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma.

Authors:  Sana Raza; Sangam Rajak; Baby Anjum; Rohit A Sinha
Journal:  Hepatoma Res       Date:  2019-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.